<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715520</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00046953</org_study_id>
    <secondary_id>R01NS060830-01A1</secondary_id>
    <secondary_id>NPARR01</secondary_id>
    <nct_id>NCT00715520</nct_id>
  </id_info>
  <brief_title>Neurobiological Principles Applied to the Rehabilitation of Stroke Patients</brief_title>
  <official_title>Neurobiological Principles Applied to the Rehabilitation of Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use (Transcranial Magnetic Stimulation) TMS or drugs to
      improve learning of movement skills and the adaptation processes in patients after stroke.
      Once investigators have determined the improving effect of TMS and the drugs on learning of
      movement skills, the study team may be able to provide information that improves
      rehabilitative treatment and helps to improve recovery after stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies have shown, that when patients learn a new motor movement, it may cause a
      change in the way the nerves act in the area of the brain that controls movement. This change
      is called use-dependent plasticity. The ability of that part of the brain, called the motor
      cortex (M1), to reorganize plays a major role in the recovery of motor deficits post-stroke;
      hence the importance for further development of rehabilitative strategies that utilize this
      potential for recovery. In this proposed study, investigators will further examine influences
      of use-dependent plasticity in the non-injured M1 of healthy subjects and injured M1 of
      stroke subjects using a combination of non-invasive cortical stimulation, medication, and
      exercise techniques. In Aim 1, investigators will test the effect of drugs that interact
      specifically with different neurotransmitter systems on use-dependent plasticity in intact M1
      of healthy humans. In Aim 2, investigators will identify the parameters for non-invasive
      transcranial magnetic stimulation (TMS) of M1 that are most effective to enhance
      use-dependent plasticity in intact healthy human M1. In Aim 3, investigators will test the
      drugs and rTMS protocols that were demonstrated to be most effective to enhance use-
      dependent plasticity in the Specific Aim 1 and 2 and apply them to participants who have
      experienced a stroke. Results from this study will help to inform future research about the
      efficacy of plasticity enhancing methods in injured M1 of stroke patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aim 1: Mean Parameter Estimate for Maximal Motor Evoked Potential (MEPmax) Derived From Stimulus Response Curves (SRC)</measure>
    <time_frame>Baseline, Post-Training 1 (Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
    <description>Motor evoked potential (MEP) amplitudes were measured prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2), and 60 minutes after the treatment (post-training 3).The MEP is elicited by transcranial magnetic stimulation (TMS) at increased intensity. Its amplitude is measured from peak to peak and expressed in millivolts (mV). Measured MEP amplitudes were plotted against the intensity to create a stimulus response curve (SRC). SRCs were modeled by a 3- parameter sigmoid function and MEPmax was extracted. Long-lasting increases in MEP amplitude indicate increases in motor cortex excitability and are associated with motor learning.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aim 1: Mean Peak Acceleration of Wrist Extension Movements</measure>
    <time_frame>Baseline, Post-Training 1 (Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
    <description>Mean peak acceleration was measured across study drug conditions prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) With Respect to Pulse</measure>
    <time_frame>Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
    <description>Mean sum of normalized MEP for repeated TMS (rTMS) conditions with respect to the pulse (-100, +300, placebo, zero) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Its amplitude is measured from peak to peak and expressed in mV. Long- lasting increases in MEP amplitude indicate increases in motor cortex excitability and are associated with motor learning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aim 2: Mean Peak Acceleration of Wrist Extension Movements With Respect to Pulse</measure>
    <time_frame>Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
    <description>Mean peak acceleration of wrist movements for repeated TMS (rTMS) conditions with respect of the TMS pulse (-100, +300, placebo, zero) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) for rTMS Treatment With Respect to Frequency</measure>
    <time_frame>Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
    <description>Mean sum of normalized MEP for the different frequencies of rTMS treatment (placebo at 0.1 Hz, 0.1 Hz, 0.25 Hz, 0.5 Hz) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aim 2: Mean Peak Acceleration for rTMS Treatment With Respect to Frequency</measure>
    <time_frame>Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
    <description>Mean peak acceleration for the different frequencies of rTMS treatment (placebo, 0.1 Hz, 0.25 Hz, 0.5 Hz) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aim 3: Mean Parameter Estimate for Maximal Motor Evoked Potential (MEPmax) Derived From Stimulus Response Curves (SRC)</measure>
    <time_frame>Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
    <description>Motor evoked potential (MEP) amplitudes were measured prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2), and 60 minutes after the treatment (post-training 3).The MEP is elicited by transcranial magnetic stimulation (TMS) at increased intensity. Its amplitude is measured from peak to peak and expressed in millivolts (mV). Measured MEP amplitudes were plotted against the intensity to create a stimulus response curve (SRC). SRCs were modeled by a 3- parameter sigmoid function and MEPmax was extracted. Long-lasting increases in MEP amplitude indicate increases in motor cortex excitability and are associated with motor learning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aim 3: Mean Peak Acceleration of Wrist Extension Movements</measure>
    <time_frame>Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
    <description>Mean peak acceleration was measured across study drug conditions prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Aim 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adult female and male subjects will receive study drugs and TMS training to measure M1 excitability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adult female and male subjects will receive repetitive TMS (rTMS) at different times or frequencies with respect to the training movement or sham stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female and male subjects who have experienced a cerebral ischemic infarction, will receive study drugs and TMS to measure M1 excitability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transcranial Magnetic Stimulation (TMS)</intervention_name>
    <description>Each TMS training session will begin with a baseline measurement lasting about 30 minutes in which brief magnetic pulses will be generated by the single—pulse and paired pulse TMS stimulator and the responses are recorded with surface EMG electrodes. Participants will be instructed to move their wrist for up to ½ hour. After these measures, rTMS will be applied to the scalp during training. Stimulation will occur at a low rate of different frequencies and different times with respect to the training movement depending on the experimental condition. In the last phase of the session post—training measurements will be done using single TMS pulses. TMS pulses and intensity with be given in random order.</description>
    <arm_group_label>Aim 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbidopa-Levodopa</intervention_name>
    <description>Participants will receive one oral dose of carbidopa-levodopa 25mg one hour prior to measuring wrist extension movements.
The order in which Carbidopa-Levodopa is given will be randomized per participant.</description>
    <arm_group_label>Aim 1</arm_group_label>
    <arm_group_label>Aim 3</arm_group_label>
    <other_name>Sinemet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>Participants will receive one oral dose of methylphenidate 40mg 2 hours prior to measuring wrist extension movements.
The order in which Methylphenidate is given will be randomized per participant.</description>
    <arm_group_label>Aim 1</arm_group_label>
    <arm_group_label>Aim 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphetamine Sulfate</intervention_name>
    <description>Participants will receive one oral dose of amphetamine sulfate 10mg 2 hours prior to measuring wrist extension movements.
The order in which Amphetamine Sulfate is given will be randomized per participant.</description>
    <arm_group_label>Aim 1</arm_group_label>
    <arm_group_label>Aim 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive one oral tablet of placebo 2 hours prior to measuring wrist extension movements.
The order in which Placebo is given will be randomized per participant.</description>
    <arm_group_label>Aim 1</arm_group_label>
    <arm_group_label>Aim 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Transcranial Magnetic Stimulation (TMS)</intervention_name>
    <description>Sham TMS pulses will be randomly administered during TMS sessions.</description>
    <arm_group_label>Aim 2</arm_group_label>
    <arm_group_label>Aim 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transcranial Magnetic Stimulation (TMS) Training</intervention_name>
    <description>TMS surface electromyographic activity will be recorded with surface electrodes mounted on the skin overlaying a forearm muscle. Single pulses of TMS at increasing intensity will be delivered to measure motor cortex excitability. Peak acceleration and TMS evoked responses in the muscle will be measured prior to the training, after completion of the training and again one hour after completion of the training.</description>
    <arm_group_label>Aim 1</arm_group_label>
    <arm_group_label>Aim 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Aims 1 and 2

        Inclusion Criteria:

          -  Normal neurological examination

          -  Ability to meet criteria of inclusion experiment

          -  Ability to give informed consent.

        Exclusion Criteria:

          -  History or neurological or psychiatric disease

          -  Abnormal MRI of brain

          -  Abnormal neuropsychological testing

          -  Intake of CNS active drugs

          -  History of seizure disorder

          -  History of migraine headaches

          -  History of anaphylaxis or allergic reactions

          -  Contraindication to TMS

        Aim 3:

        Inclusion Criteria:

          -  Cerebral ischemic infarction more than 6 months prior to entering the study

          -  Single lesion as defined by MRI of the brain affecting the primary motor output system
             of the hand at a cortical (M1) level or subcortical level, or unilateral, and
             supratentorial in absence of history of a previous symptomatic stroke within 3 months
             of the current stroke

          -  Dense paresis of the hand for more than three days after cerebral infarction (MRC of &lt;
             4- of wrist- and finger extension/flexion movements)

          -  Good functional recovery of hand function as defined by MRC of 4 or 4+ of wrist- and
             finger extension/flexion movements

          -  Ability to perform wrist extension movements

          -  Ability to meet criteria of inclusion experiment

          -  Ability to give informed consent

          -  Ability of TMS to elicit a measurable MEP of &gt; 100 μV and an increase in MEP amplitude
             with increasing stimulus intensity (up to 100% of MSO) of at least 20% over MEP
             amplitude at MT

        Exclusion Criteria:

          -  History or neurological or psychiatric disease, including bipolar disorder

          -  Intake of CNS active drugs

          -  History of seizure disorder

          -  History of migraine headaches

          -  History of anaphylaxis or allergic reactions

          -  Contraindication to TMS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cathrin M Buetefisch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2008</study_first_submitted>
  <study_first_submitted_qc>July 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <results_first_submitted>October 12, 2017</results_first_submitted>
  <results_first_submitted_qc>October 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 16, 2017</results_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Cathrin Buetefisch</investigator_full_name>
    <investigator_title>Dr. Cathrin Buetefisch</investigator_title>
  </responsible_party>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Stroke</keyword>
  <keyword>Plasticity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited between April 2007 and August 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Aim 1</title>
          <description>Healthy adult female and male subjects received study drugs and TMS to measure M1 excitability.</description>
        </group>
        <group group_id="P2">
          <title>Aim 2</title>
          <description>Healthy adult female and male subjects received TMS prior to measuring wrist extension movements.</description>
        </group>
        <group group_id="P3">
          <title>Aim 3</title>
          <description>Female and male subjects who have experienced a cerebral ischemic infarction will receive study drugs and TMS to measure M1 excitability.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants included in the baseline analysis received a study intervention and completed all study procedures.</population>
      <group_list>
        <group group_id="B1">
          <title>Aim 1</title>
          <description>Healthy adult female and male subjects received study drugs and TMS to measure M1 excitability.</description>
        </group>
        <group group_id="B2">
          <title>Aim 2</title>
          <description>Healthy adult female and male subjects received TMS prior to measuring wrist extension movements.</description>
        </group>
        <group group_id="B3">
          <title>Aim 3</title>
          <description>Female and male subjects who have experienced a cerebral ischemic infarction will receive study drugs and TMS to measure M1 excitability.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="1"/>
                    <count group_id="B4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="1"/>
                    <count group_id="B4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="1"/>
                    <count group_id="B4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aim 1: Mean Parameter Estimate for Maximal Motor Evoked Potential (MEPmax) Derived From Stimulus Response Curves (SRC)</title>
        <description>Motor evoked potential (MEP) amplitudes were measured prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2), and 60 minutes after the treatment (post-training 3).The MEP is elicited by transcranial magnetic stimulation (TMS) at increased intensity. Its amplitude is measured from peak to peak and expressed in millivolts (mV). Measured MEP amplitudes were plotted against the intensity to create a stimulus response curve (SRC). SRCs were modeled by a 3- parameter sigmoid function and MEPmax was extracted. Long-lasting increases in MEP amplitude indicate increases in motor cortex excitability and are associated with motor learning.</description>
        <time_frame>Baseline, Post-Training 1 (Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
        <population>Analysis was completed in Aim 1 participants per protocol for the placebo condition. One subject was not included in the analysis due to corrupt data.</population>
        <group_list>
          <group group_id="O1">
            <title>Aim 1</title>
            <description>Healthy adult female and male subjects received study drugs and TMS to measure M1 excitability.</description>
          </group>
        </group_list>
        <measure>
          <title>Aim 1: Mean Parameter Estimate for Maximal Motor Evoked Potential (MEPmax) Derived From Stimulus Response Curves (SRC)</title>
          <description>Motor evoked potential (MEP) amplitudes were measured prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2), and 60 minutes after the treatment (post-training 3).The MEP is elicited by transcranial magnetic stimulation (TMS) at increased intensity. Its amplitude is measured from peak to peak and expressed in millivolts (mV). Measured MEP amplitudes were plotted against the intensity to create a stimulus response curve (SRC). SRCs were modeled by a 3- parameter sigmoid function and MEPmax was extracted. Long-lasting increases in MEP amplitude indicate increases in motor cortex excitability and are associated with motor learning.</description>
          <population>Analysis was completed in Aim 1 participants per protocol for the placebo condition. One subject was not included in the analysis due to corrupt data.</population>
          <units>mV</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Placebo - MEPmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 Placebo - MEPmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread=".33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 Placebo - MEPmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Amphetamine Sulfate - MEPmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".73" spread=".10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 Ampletamine Sulfate - MEPmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread=".26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 Amphetamine Sulfate - MEPmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Methylphenidate - MEPmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 Methylphenidate - MEPmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread=".12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 Methylphenidate - MEPmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Carbidopa-Levodopa - MEPmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread=".62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 Carbidopa-Levodopa - MEPmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread=".26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 Carbidopa-Levodopa - MEPmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aim 1: Mean Peak Acceleration of Wrist Extension Movements</title>
        <description>Mean peak acceleration was measured across study drug conditions prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface.</description>
        <time_frame>Baseline, Post-Training 1 (Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
        <population>Analysis was completed in Aim 1 participants per protocol. One subject was not included in the analysis due to corrupt data.</population>
        <group_list>
          <group group_id="O1">
            <title>Aim 1</title>
            <description>Healthy adult female and male subjects received study drugs and TMS to measure M1 excitability.</description>
          </group>
        </group_list>
        <measure>
          <title>Aim 1: Mean Peak Acceleration of Wrist Extension Movements</title>
          <description>Mean peak acceleration was measured across study drug conditions prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface.</description>
          <population>Analysis was completed in Aim 1 participants per protocol. One subject was not included in the analysis due to corrupt data.</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread=".35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread=".21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread=".30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Amphetamine Sulfate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread=".33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Amphetamine Sulfate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread=".31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Amphetamine Sulfate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread=".39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Methylphenidate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread=".30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Methylphenidate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread=".16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Methylphenidate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread=".25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Carbidopa-Levodopa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread=".39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Carbidopa-Levodopa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread=".27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Carbidopa-Levodopa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread=".38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) With Respect to Pulse</title>
        <description>Mean sum of normalized MEP for repeated TMS (rTMS) conditions with respect to the pulse (-100, +300, placebo, zero) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Its amplitude is measured from peak to peak and expressed in mV. Long- lasting increases in MEP amplitude indicate increases in motor cortex excitability and are associated with motor learning.</description>
        <time_frame>Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
        <population>Analysis was completed in Aim 2 participants per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Aim 2</title>
            <description>Healthy adult female and male subjects received TMS prior to measuring wrist extension movements.</description>
          </group>
        </group_list>
        <measure>
          <title>Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) With Respect to Pulse</title>
          <description>Mean sum of normalized MEP for repeated TMS (rTMS) conditions with respect to the pulse (-100, +300, placebo, zero) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Its amplitude is measured from peak to peak and expressed in mV. Long- lasting increases in MEP amplitude indicate increases in motor cortex excitability and are associated with motor learning.</description>
          <population>Analysis was completed in Aim 2 participants per protocol.</population>
          <units>millivolts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Pulse (zero)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".39" spread=".36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Pulse (zero)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".66" spread=".74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Pulse (zero)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".63" spread=".63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - Pulse (zero)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".69" spread=".76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Pulse (placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".40" spread=".38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Pulse (placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".54" spread=".57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Pulse (placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".51" spread=".59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - Pulse (placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".52" spread=".59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Pulse (-100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".39" spread=".37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Pulse (-100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".56" spread=".54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Pulse (-100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".60" spread=".67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - Pulse (-100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".61" spread=".63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Pulse (+300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".38" spread=".38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Pulse (+300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".54" spread=".51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Pulse (+300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".48" spread=".45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - Pulse (+300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".51" spread=".50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aim 2: Mean Peak Acceleration of Wrist Extension Movements With Respect to Pulse</title>
        <description>Mean peak acceleration of wrist movements for repeated TMS (rTMS) conditions with respect of the TMS pulse (-100, +300, placebo, zero) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface.</description>
        <time_frame>Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
        <population>Analysis was completed in Aim 2 participants per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Aim 2</title>
            <description>Healthy adult female and male subjects received TMS prior to measuring wrist extension movements.</description>
          </group>
        </group_list>
        <measure>
          <title>Aim 2: Mean Peak Acceleration of Wrist Extension Movements With Respect to Pulse</title>
          <description>Mean peak acceleration of wrist movements for repeated TMS (rTMS) conditions with respect of the TMS pulse (-100, +300, placebo, zero) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface.</description>
          <population>Analysis was completed in Aim 2 participants per protocol.</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Pulse (zero)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread=".31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Pulse (zero)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread=".30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Pulse (zero)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread=".34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - Pulse (zero)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread=".37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Pulse (placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread=".25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Pulse (placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread=".24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Pulse (placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread=".24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - Pulse (placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread=".30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Pulse (-100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread=".34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Pulse (-100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread=".30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Pulse (-100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread=".34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - Pulse (-100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread=".27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Pulse (+300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread=".34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Pulse (+300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread=".35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Pulse (+300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread=".40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - Pulse (+300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread=".43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) for rTMS Treatment With Respect to Frequency</title>
        <description>Mean sum of normalized MEP for the different frequencies of rTMS treatment (placebo at 0.1 Hz, 0.1 Hz, 0.25 Hz, 0.5 Hz) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning.</description>
        <time_frame>Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
        <population>Analysis was completed in Aim 2 participants per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Aim 2</title>
            <description>Healthy adult female and male subjects received TMS prior to measuring wrist extension movements.</description>
          </group>
        </group_list>
        <measure>
          <title>Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) for rTMS Treatment With Respect to Frequency</title>
          <description>Mean sum of normalized MEP for the different frequencies of rTMS treatment (placebo at 0.1 Hz, 0.1 Hz, 0.25 Hz, 0.5 Hz) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning.</description>
          <population>Analysis was completed in Aim 2 participants per protocol.</population>
          <units>millivolts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".67" spread=".79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".93" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".94" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - .1 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".71" spread=".83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - .1 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - .1 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - .1 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - .25 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".67" spread=".84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - .25 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".90" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - .25 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".90" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - .25 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".98" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - .5 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".64" spread=".74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - .5 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".92" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - .5 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".90" spread=".99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - .5 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".84" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aim 2: Mean Peak Acceleration for rTMS Treatment With Respect to Frequency</title>
        <description>Mean peak acceleration for the different frequencies of rTMS treatment (placebo, 0.1 Hz, 0.25 Hz, 0.5 Hz) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface.</description>
        <time_frame>Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
        <population>Analysis was completed in Aim 2 participants per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Aim 2</title>
            <description>Healthy adult female and male subjects received TMS prior to measuring wrist extension movements.</description>
          </group>
        </group_list>
        <measure>
          <title>Aim 2: Mean Peak Acceleration for rTMS Treatment With Respect to Frequency</title>
          <description>Mean peak acceleration for the different frequencies of rTMS treatment (placebo, 0.1 Hz, 0.25 Hz, 0.5 Hz) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface.</description>
          <population>Analysis was completed in Aim 2 participants per protocol.</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread=".25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread=".24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread=".24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread=".30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - .1 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread=".31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - .1 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread=".30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - .1 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread=".34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - .1 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread=".37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - .25 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread=".26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - .25 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread=".44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - .25 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread=".37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - .25 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread=".47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - .5 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread=".23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 1 - .5 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread=".30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 2 - .5 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread=".29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Training 3 - .5 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread=".31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aim 3: Mean Parameter Estimate for Maximal Motor Evoked Potential (MEPmax) Derived From Stimulus Response Curves (SRC)</title>
        <description>Motor evoked potential (MEP) amplitudes were measured prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2), and 60 minutes after the treatment (post-training 3).The MEP is elicited by transcranial magnetic stimulation (TMS) at increased intensity. Its amplitude is measured from peak to peak and expressed in millivolts (mV). Measured MEP amplitudes were plotted against the intensity to create a stimulus response curve (SRC). SRCs were modeled by a 3- parameter sigmoid function and MEPmax was extracted. Long-lasting increases in MEP amplitude indicate increases in motor cortex excitability and are associated with motor learning.</description>
        <time_frame>Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
        <population>No sufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Aim 3</title>
            <description>Female and male subjects who have experienced a cerebral ischemic infarction will receive study drugs and TMS to measure M1 excitability.</description>
          </group>
        </group_list>
        <measure>
          <title>Aim 3: Mean Parameter Estimate for Maximal Motor Evoked Potential (MEPmax) Derived From Stimulus Response Curves (SRC)</title>
          <description>Motor evoked potential (MEP) amplitudes were measured prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2), and 60 minutes after the treatment (post-training 3).The MEP is elicited by transcranial magnetic stimulation (TMS) at increased intensity. Its amplitude is measured from peak to peak and expressed in millivolts (mV). Measured MEP amplitudes were plotted against the intensity to create a stimulus response curve (SRC). SRCs were modeled by a 3- parameter sigmoid function and MEPmax was extracted. Long-lasting increases in MEP amplitude indicate increases in motor cortex excitability and are associated with motor learning.</description>
          <population>No sufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aim 3: Mean Peak Acceleration of Wrist Extension Movements</title>
        <description>Mean peak acceleration was measured across study drug conditions prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface.</description>
        <time_frame>Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)</time_frame>
        <population>No sufficient data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Aim 3</title>
            <description>Female and male subjects who have experienced a cerebral ischemic infarction will receive study drugs and TMS to measure M1 excitability.</description>
          </group>
        </group_list>
        <measure>
          <title>Aim 3: Mean Peak Acceleration of Wrist Extension Movements</title>
          <description>Mean peak acceleration was measured across study drug conditions prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface.</description>
          <population>No sufficient data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the duration of the study (6 years, 6 months).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aim 1</title>
          <description>Healthy adult female and male subjects received study drugs and TMS to measure M1 excitability.</description>
        </group>
        <group group_id="E2">
          <title>Aim 2</title>
          <description>Healthy adult female and male subjects received TMS prior to measuring wrist extension movements.</description>
        </group>
        <group group_id="E3">
          <title>Aim 3</title>
          <description>Female and male subjects who have experienced a cerebral ischemic infarction will receive study drugs and TMS to measure M1 excitability.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertio</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Facial Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Parathesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Blood Pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Target enrollment for aim 3 was not me due to difficulty identifying participants that met the inclusion criteria. Therefore the study team did not have a sufficient sample size to complete any data analysis for this aim.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Cathrin Buetefisch</name_or_title>
      <organization>Emory University</organization>
      <phone>4047121894</phone>
      <email>cathrin.buetefisch@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

